Abstract 5035
Background
Although pancreatic cancer has irregular shape in three-dimensional (3D), when T staging by imaging, only the axial plane is generally used to measure the largest diameter of the mass. We analysed the size of the pancreatic cancer from multi-plane and 3D reconstructed CT images and investigated their clinical usefulness.
Methods
Patients who underwent surgery for pancreatic adenocarcinoma from 2009 to 2016 were included in this study. We measured the largest diameter of pancreatic cancer in axial, coronal, and sagittal planes of CT. In addition, semi-automated segmentation was performed and three-dimensional (3D) maximal diameter and cancer volume were obtained. The obtained data were compared with the actual pathology report and the effect of each value on prognosis was analyzed by receiver operating characteristics (ROC) curves.
Results
A total of 183 patients were analyzed. The maximal pathologic diameter of cancer was 3.4 ± 1.4 cm and median survival was 18.1 months. The maximal diameters measured in axial, coronal, and sagittal planes were 2.9 ± 1.1, 3.2 ± 1.0, and 3.2 ± 0.9, respectively, which were significantly smaller than pathologic data (all p < 0.05 by paired T test). The longest diameter among measured on the 3 planes (3.4 ± 1.1) were not significantly different from that of pathologic report and maximal diameter from 3D image (3.8 ± 1.3) was larger than pathologic diameter. Cancer volume demonstrated the higher area under the ROC curve [0.714, (95% confidence interval: 0.640-0.788)] in predicting early death within 18 months than any measured diameter.
Conclusions
The diameter of pancreatic cancer needs to be measured on all of axial, coronal, and sagittal planes of CT. Cancer volume had a stronger correlation with overall survival than cancer diameter.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Research Foundation of Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2551 - Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: an exploratory analysis of the GIM2 trial.
Presenter: Benedetta Conte
Session: Poster Display session 2
Resources:
Abstract
3426 - High dose Neo-adjuvant chemotherapy in Triple-Negative breast cancer with evidence of homologous recombination deficiency (HRD).
Presenter: Sonja Vliek
Session: Poster Display session 2
Resources:
Abstract
3792 - Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials
Presenter: Gustavo Werutsky
Session: Poster Display session 2
Resources:
Abstract
4044 - Estimating radiotherapy-induced cardiovascular mortality in female breast cancer patients.
Presenter: Mark De Ridder
Session: Poster Display session 2
Resources:
Abstract
719 - 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)
Presenter: Justin Stebbing
Session: Poster Display session 2
Resources:
Abstract
3595 - Adjuvant chemotherapy in elderly breast cancer patients: pattern of use and impact on overall survival
Presenter: Axel Berthelot
Session: Poster Display session 2
Resources:
Abstract
3992 - Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): a propensity score-matched study.
Presenter: Maria Vittoria Dieci
Session: Poster Display session 2
Resources:
Abstract
3477 - Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): an epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)
Presenter: Mellissa Williamson
Session: Poster Display session 2
Resources:
Abstract
3928 - Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study
Presenter: Hans Tesch
Session: Poster Display session 2
Resources:
Abstract
2184 - The clinical impact of adjuvant dose-dense sequential chemotherapy (dds-CT) in patients with high-risk operable breast cancer (BC); pooled analysis of 6 clinical trials.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract